[FG] Binder Mascha

Paschold, L. et al. (2024) ‘Inflammatory signature and restriction of adaptive immunity are associated with unfavorable outcomes on immune checkpoint blockade in patients with advanced head and neck squamous cell carcinoma’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.11.29.24317276.

Tintelnot, J. et al. (2024) ‘Inflammatory stress determines the need for chemotherapy in patients with HER2-positive esophagogastric adenocarcinoma receiving targeted and immunotherapy’, Cancer Immunology Research [Preprint]. Available at: https://doi.org/10.1158/2326-6066.cir-24-0561.

Steinmann, L.A. et al. (2024) ‘Differential associations between SARS-CoV-2 infection, perceived burden of the pandemic and mental health in the German population-based cohort for digital health research’, Psychiatry Research, 341, p. 116140. Available at: https://doi.org/10.1016/j.psychres.2024.116140.

Willscher, E. et al. (2024) ‘T-cell receptor architecture and clonal tiding provide insight into the transformation trajectory of peripheral T-cell lymphomas’, Haematologica [Preprint]. Available at: https://doi.org/10.3324/haematol.2024.285395.

Schultheiß, C. et al. (2024) ‘A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors’, Science Advances, 10(34). Available at: https://doi.org/10.1126/sciadv.adl3975.

Schultheiß, C. et al. (2024) ‘B cells expressing mutated IGHV1-69–encoded antigen receptors related to virus neutralization show lymphoma-like transcriptomes in patients with chronic HCV infection’, Hepatology Communications, 8(8). Available at: https://doi.org/10.1097/hc9.0000000000000503.

Erhart, C.-C. et al. (2024) ‘Prognostic value of KRAS G12C in advanced non-small cell lung cancer with high PD-L1 expression treated with upfront immunotherapy: a systematic review and meta-analysis’, Swiss Medical Weekly, 154(7), p. 3695. Available at: https://doi.org/10.57187/s.3695.

Schmidt-Barbo, P. et al. (2024) ‘Detection of disease-specific signatures in B cell repertoires of lymphomas using machine learning’, PLOS Computational Biology, 20(7), p. e1011570. Available at: https://doi.org/10.1371/journal.pcbi.1011570.

Thiele, B. et al. (2024) ‘Trifluridine/tipiracil based chemoradiation in locally advanced rectal cancer - The phase I/II TARC trial’, Clinical Colorectal Cancer [Preprint]. Available at: https://doi.org/10.1016/j.clcc.2024.06.003.

Haug, N. et al. (2024) ‘Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients’, Quality of Life Research, 33(4), pp. 1085–1094. Available at: https://doi.org/10.1007/s11136-023-03588-7.

Cardon, A. et al. (2024) ‘The immune profile of circulating autoreactive CD4 T cells is imprinted through tissue activation during autoimmune liver diseases’. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2024.03.26.586770.

Thuss-Patience, Peter et al. (2024) ‘Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma’, JAMA Network Open, 7(1), p. e2352830. Available at: https://doi.org/10.1001/jamanetworkopen.2023.52830.

Brandt, Anna et al. (2024) ‘Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial’, Frontiers in Oncology, 14. Available at: https://doi.org/10.3389/fonc.2024.1283266.

Diexer, Sophie et al. (2024) ‘Insights into early recovery from Long COVID—results from the German DigiHero Cohort’, Scientific Reports, 14. Available at: https://doi.org/10.1038/s41598-024-59122-3.

Fischer, Claudia et al. (2024) ‘SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition’, npj Vaccines, 9(1). Available at: https://doi.org/10.1038/s41541-024-00815-1.

Glaser, Nadine et al. (2024) ‘The contribution of SARS-CoV-2 to the burden of acute respiratory infections in winter season 2022/2023: results from the DigiHero study’, International Journal of Infectious Diseases, 144. Available at: https://doi.org/10.1016/j.ijid.2024.107057.

Klee, B. et al. (2024) ‘Household transmission of Omicron variant of SARS-CoV-2 under conditions of hybrid immunity—a prospective study in Germany’, Infection [Preprint]. Available at: https://doi.org/10.1007/s15010-024-02352-4.

Märkl, Florian et al. (2024) ‘Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia’, Nature Communications, 15. Available at: https://doi.org/10.1038/s41467-024-45378-w.

Mohme, Malte et al. (2024) ‘SARS-CoV-2-associated T-cell infiltration in the central nervous system’, Clinical and Translational Immunology, 13(2). Available at: https://doi.org/10.1002/cti2.1487.

Padoan, Benedetta et al. (2024) ‘NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells’, Cell Reports, 43. Available at: https://doi.org/10.1016/j.celrep.2024.114089.

Schorb, Elisabeth et al. (2024) ‘High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial’, The Lancet Haematology, null. Available at: https://doi.org/10.1016/s2352-3026(23)00371-x.

Diexer, S. et al. (2023) ‘Association between virus variants, vaccination, previous infections, and post-COVID-19 risk’, International Journal of Infectious Diseases, 136, pp. 14–21. Available at: https://doi.org/10.1016/j.ijid.2023.08.019.

Klee, B. et al. (2023) ‘Regional Differences in Uptake of Vaccination against COVID-19 and Influenza in Germany: Results from the DigiHero Cohort’, Vaccines, 11(11). Available at: https://doi.org/10.3390/vaccines11111640.

Mezger, N.C.S. et al. (2023) ‘Guideline Concordance of Treatment and Outcomes Among Adult Non-Hodgkin Lymphoma Patients in Sub-Saharan Africa: A Multinational, Population-Based Cohort’, Oncologist, 28(11), pp. E1017–E1030. Available at: https://doi.org/10.1093/oncolo/oyad157.

Schmidt-Barbo, P. et al. (2023) Detection of disease-specific signatures in B cell repertoires of lymphomas using machine learning. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.10.05.561150.

Märkl, F. et al. (2023) Mutation-specific CAR T cells as precision therapy for IGLV3-21^R110expressing high-risk chronic lymphocytic leukemia. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.09.29.560075.

Klee, B. et al. (2023) Regional Differences in Uptake of Vaccination against COVID-19 and Influenza in Germany—Results from the Digi-Hero Cohort. MDPI AG. Available at: https://doi.org/10.20944/preprints202309.1465.v1.

Brioli, A. et al. (2023) ‘Pomalidomide combinations are a safe and effective option after daratumumab failure’, Journal of Cancer Research and Clinical Oncology, 149(9), pp. 6569–6574. Available at: https://doi.org/10.1007/s00432-023-04637-x.

Jaeger, A. et al. (2023) ‘Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms’, Blood, 141(23), pp. 2824–2840. Available at: https://doi.org/10.1182/blood.2022015653.

Groß, E. et al. (2023) ‘SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters’, Cancers, 15(11). Available at: https://doi.org/10.3390/cancers15113043.

Katzerke, C. et al. (2023) ‘Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome’, Blood Advances, 7(12), pp. 2811–2824. Available at: https://doi.org/10.1182/bloodadvances.2022008510.

Gottschick, C. et al. (2023) ‘Mental health in Germany in the first weeks of the Russo-Ukrainian war’, BJPsych Open, 9(3). Available at: https://doi.org/10.1192/bjo.2023.21.

Schultheiß, C. et al. (2023) ‘Immune signatures in variant syndromes of primary biliary cholangitis and autoimmune hepatitis’, Hepatology Communications, 7(5). Available at: https://doi.org/10.1097/HC9.0000000000000123.

Hayoz S et al. (2023) ‘Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK).’, BMJ open, 13(4), p. e068490. Available at: https://doi.org/10.1136/bmjopen-2022-068490.

Tintelnot, J. et al. (2023) Data from Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies. American Association for Cancer Research (AACR). Available at: https://doi.org/10.1158/1535-7163.c.6538192.v1.

Claaß, L.V. et al. (2023) ‘No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination’, Cancer Medicine, 12(8), pp. 9313–9321. Available at: https://doi.org/10.1002/cam4.5687.

Schultheiß, C. et al. (2023) IGHV1-69 BCRs with virus-neutralizing mutations show lymphoma-like transcriptomes in patients with chronic HCV infection. Research Square Platform LLC. Available at: https://doi.org/10.21203/rs.3.rs-2719495/v1.

Hoang-Xuan K et al. (2023) ‘European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL).’, Neuro-oncology, 25(1), pp. 37–53. Available at: https://doi.org/10.1093/neuonc/noac196.

Brandt, Anna et al. (2023) ‘Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma’, Cancers, 15. Available at: https://doi.org/10.3390/cancers15072051.

Finazzi, Tobias et al. (2023) ‘Patient Reported Outcome Measures (PROMs) in a multidisciplinary lung cancer centre: a value-based healthcare pilot project’, SOCH. Schweiz (SOCH), 1 January. Available at: https://www.researchgate.net/publication/378675035_Patient_Reported_Outcome_Measures_PROMs_in_a_multidisciplinary_lung_cancer_centre_a_value-based_healthcare_pilot_project.

Gloy, Viktoria et al. (2023) ‘The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020’, International Journal of Cancer, 152, pp. 2474–2484. Available at: https://doi.org/10.1002/ijc.34473.

Lübbering, D. et al. (2023) ‘Autoantigen-selected B cells are bystanders in spontaneous T cell-driven experimental autoimmune hepatitis’, Immunology, 170, pp. 214–229. Available at: https://doi.org/10.1111/imm.13665.

Marcinkevics, Ricards et al. (2023) ‘Machine learning analysis of humoral and cellular responses to SARS-CoV-2 infection in young adults’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1158905.

Martens, U.M. et al. (2023) ‘The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice’, BMC Cancer, 23. Available at: https://doi.org/10.1186/s12885-023-11046-3.

Massag, J. et al. (2023) ‘Anxiety, depressive symptoms, and distress over the course of the war in Ukraine in three federal states in Germany’, Frontiers in Psychiatry, 14. Available at: https://doi.org/10.3389/fpsyt.2023.1167615.

Paschold, Lisa et al. (2023) ‘T cell repertoire breadth is associated with the number of acute respiratory infections in the LoewenKIDS birth cohort’, Scientific Reports, 13. Available at: https://doi.org/10.1038/s41598-023-36144-x.

Paschold, Lisa et al. (2023) ‘First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial’, Journal for ImmunoTherapy of Cancer, 11. Available at: https://doi.org/10.1136/jitc-2023-006678.

Schultheiß, C. et al. (2023) ‘Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19’, Journal of Medical Virology, 95. Available at: https://doi.org/10.1002/jmv.28364.

Stein, Alexander, Thiele, Benjamin and Binder, Mascha (2023) ‘Perioperative concepts for resectable adenocarcinomas of the stomach and gastroesophageal junction: Standard of Care and future developments’, Tumor Diagnostik und Therapie. 26.09.2023, 44(8), pp. 540–544. Available at: https://doi.org/10.1055/a-2073-0206.

Tintelnot, Joseph et al. (2023) ‘Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)’, Frontiers in Oncology, 13. Available at: https://doi.org/10.3389/fonc.2023.1272175.

Ellingsen, E.B. et al. (2022) ‘Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination’, Journal of Translational Medicine, 20(1). Available at: https://doi.org/10.1186/s12967-022-03624-z.

Grimm, J. and Binder, M. (2022) ‘Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome’, Signal Transduction and Targeted Therapy, 7(1). Available at: https://doi.org/10.1038/s41392-022-01143-3.

Stanczak MA et al. (2022) ‘Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.’, Science translational medicine, 14(669), p. eabj1270. Available at: https://doi.org/10.1126/scitranslmed.abj1270.

Schmitt AM et al. (2022) ‘Characteristics and survival of patients with cancer with intended off-label use-a cohort study.’, BMJ open, 12(5), p. e060453. Available at: https://doi.org/10.1136/bmjopen-2021-060453.

Jonas, H. et al. (2022) ‘Early relapse detection by monitoring of circulating cell-free DNA in patients with localized head and neck squamous cell carcinoma: A subgroup analysis of the multicenter randomized clinical trial IMSTAR-HN’, Oral Oncology, 126. Available at: https://doi.org/10.1016/j.oraloncology.2022.105733.

Jotschke, S. et al. (2022) ‘Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO)’, Cancers, 14(6). Available at: https://doi.org/10.3390/cancers14061544.

Paschold, L. and Binder, M. (2022) ‘Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer’, Current Oncology, 29(3), pp. 1430–1441. Available at: https://doi.org/10.3390/curroncol29030120.

Schaffrath, J. et al. (2022) ‘Correlation of nutrition-associated parameters with non-relapse mortality in allogeneic hematopoietic stem cell transplantation’, Annals of Hematology, 101(3), pp. 681–691. Available at: https://doi.org/10.1007/s00277-021-04736-0.

Claaß, L.V. et al. (2022) ‘PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition’, Frontiers in Oncology, 12. Available at: https://doi.org/10.3389/fonc.2022.941666.

Grimm, J. et al. (2022) ‘Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients’, Blood Cancer Journal, 12(1). Available at: https://doi.org/10.1038/s41408-022-00615-7.

Gryaznov, D. et al. (2022) ‘Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIrit recommendations in Switzerland, CAnada and GErmany (ASPIRE-SCAGE)’, BMJ Open, 12(5), p. e053417. Available at: https://doi.org/10.1136/bmjopen-2021-053417.

Kasenda, B. et al. (2022) ‘Targeting immunoliposomes to EGFR-positive glioblastoma’, ESMO Open, 7. Available at: https://doi.org/10.1016/j.esmoop.2021.100365.

Paschold, L. et al. (2022) ‘Rapid Hypermutation B Cell Trajectory Recruits Previously Primed B Cells Upon Third SARS-Cov-2 mRNA Vaccination’, Frontiers in Immunology, 13. Available at: https://doi.org/10.3389/fimmu.2022.876306.

Paschold, L. et al. (2022) ‘Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21^R110 chronic lymphocytic leukemia’, Blood Cancer Journal, 12. Available at: https://doi.org/10.1038/s41408-022-00650-4.

Schultheiß, C. and Binder, M. (2022) ‘Overcoming unintended immunogenicity in immunocompetent mouse models of metastasis: the case of GFP’, Signal Transduction and Targeted Therapy, 7. Available at: https://doi.org/10.1038/s41392-022-00929-9.

Schultheiß, C. et al. (2022) ‘B cells in autoimmune hepatitis: bystanders or central players?’, Seminars in Immunopathology, 44, pp. 411–427. Available at: https://doi.org/10.1007/s00281-022-00937-5.

Schultheiß, C. et al. (2022) ‘The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19’, Cell Reports Medicine, 3. Available at: https://doi.org/10.1016/j.xcrm.2022.100663.

Speich, B. et al. (2022) ‘Nonregistration, discontinuation, and nonpublication of randomized trials: a repeated metaresearch analysis’, PLoS Med, 19(4), p. e1003980. Available at: https://doi.org/10.1371/journal.pmed.1003980.

Stein, A. et al. (2022) ‘Efficacy of Ipilimumab vs FOLFOX in Combination with Nivolumab and Trastuzumab in Patients with Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial’, pp. 1150–1158. Available at: https://doi.org/10.1001/jamaoncol.2022.2228.

Tintelnot, J. et al. (2022) ‘Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer’, Frontiers in Oncology, 12. Available at: https://doi.org/10.3389/fonc.2022.993611.

van Wilpe, S. et al. (2022) ‘Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype’, OncoImmunology, 11(1). Available at: https://doi.org/10.1080/2162402x.2022.2094133.

Schümann, F.L. et al. (2021) ‘Divergent effects of ezh1 and ezh2 protein expression on the prognosis of patients with t-cell lymphomas’, Biomedicines, 9(12). Available at: https://doi.org/10.3390/biomedicines9121842.

Paschold, L. et al. (2021) ‘Evolutionary clonal trajectories in nodular lymphocyte-predominant Hodgkin lymphoma with high risk of transformation’, Haematologica, 106(10), pp. 2654–2666. Available at: https://doi.org/10.3324/haematol.2021.278427.

Schümann, F.L. et al. (2021) ‘Rbmx protein expression in t-cell lymphomas predicts chemotherapy response and prognosis’, Cancers, 13(19). Available at: https://doi.org/10.3390/cancers13194788.

Taji Heravi A et al. (2021) ‘Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials.’, JAMA network open, 4(10), p. e2131503. Available at: https://doi.org/10.1001/jamanetworkopen.2021.31503.

Bußmann, L. et al. (2021) ‘Analyzing tyrosine kinase activity in head and neck cancer by functional kinomics: Identification of hyperactivated Src family kinases as prognostic markers and potential targets’, International Journal of Cancer, 149(5), pp. 1166–1180. Available at: https://doi.org/10.1002/ijc.33606.

Thiele, B. et al. (2021) ‘Outcome of a Real-World Patient Cohort with Secondary CNS Lymphoma Treated with High-Intensity Chemoimmunotherapy and Autologous Stem Cell Transplantation’, Oncology Research and Treatment, 44(7), pp. 375–380. Available at: https://doi.org/10.1159/000517531.

Wass, M. et al. (2021) ‘A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy’, Leukemia, 35(3), pp. 701–711. Available at: https://doi.org/10.1038/s41375-020-0892-z.

Grehl, C. et al. (2021) ‘Detection of sars‐cov‐2 derived small rnas and changes in circulating small rnas associated with covid‐19’, Viruses, 13. Available at: https://doi.org/10.3390/v13081593.

Herbrand, Amanda Katherina et al. (2021) ‘Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs’, Jama Network Open, 4(3), p. e210380. Available at: https://doi.org/10.1001/jamanetworkopen.2021.0380.

Lohner, Szimonetta et al. (2021) ‘Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study’, Journal of Clinical Epidemiology, 139, pp. 340–349. Available at: https://doi.org/10.1016/j.jclinepi.2021.05.011.

Paschold, L. et al. (2021) ‘SARS-CoV-2-specific antibody rearrangements in prepandemic immune repertoires of risk cohorts and patients with COVID-19’, Journal of Clinical Investigation, 131. Available at: https://doi.org/10.1172/jci142966.

Porritt, R.A. et al. (2021) ‘The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children’, Journal of Clinical Investigation, 131(20). Available at: https://doi.org/10.1172/jci151520.

Porritt, R.A. et al. (2021) ‘HLA class I–associated expansion of TRBV11-2 T cells in multisystem inflammatory syndrome in children’, Journal of Clinical Investigation, 131. Available at: https://doi.org/10.1172/jci146614.

Schultheiß, C. et al. (2021) ‘Maturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19’, iScience, 24. Available at: https://doi.org/10.1016/j.isci.2021.103325.

Schultheiß, C. et al. (2021) ‘Next-Generation Immunosequencing Reveals Pathological T-Cell Architecture in Autoimmune Hepatitis’, Hepatology, 73, pp. 1436–1448. Available at: https://doi.org/10.1002/hep.31473.

Simnica, D. et al. (2021) ‘Landscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts’, Clinical and Translational Immunology, 10. Available at: https://doi.org/10.1002/cti2.1340.

von Wenserski, L. et al. (2021) ‘SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2’, Leukemia, 35, pp. 1073–1086. Available at: https://doi.org/10.1038/s41375-020-01025-z.

Zhao, Y. et al. (2021) ‘Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients’, Science Immunology, 6. Available at: https://doi.org/10.1126/sciimmunol.abf6692.

Zech, H.B. et al. (2020) ‘Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma’, Future Oncology, 16(36), pp. 3035–3043. Available at: https://doi.org/10.2217/fon-2020-0595.

Cheng, M.H. et al. (2020) ‘Superantigenic character of an insert unique to SARS-CoV-2 spike supported by skewed TCR repertoire in patients with hyperinflammation’, Proceedings of the National Academy of Sciences of the United States of America, 117(41), pp. 25254–25262. Available at: https://doi.org/10.1073/pnas.2010722117.

Montesinos-Rongen M et al. (2020) ‘Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.’, The Journal of molecular diagnostics : JMD, 22(10), pp. 1300–1307. Available at: https://doi.org/10.1016/j.jmoldx.2020.07.002.

Simnica, D. et al. (2020) ‘Targeting the Mutational Landscape of Bystander Cells: Drug-Promoted Blood Cancer From High-Prevalence Pre-neoplasias in Patients on BRAF Inhibitors’, Frontiers in Oncology, 10. Available at: https://doi.org/10.3389/fonc.2020.540030.

Schorb E et al. (2020) ‘High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study.’, Blood advances, 4(14), pp. 3378–3381. Available at: https://doi.org/10.1182/bloodadvances.2020002064.

Mezger, N.C.S. et al. (2020) ‘Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa’, British Journal of Haematology, 190(2), pp. 209–221. Available at: https://doi.org/10.1111/bjh.16575.

Terziev, D. et al. (2020) ‘Impact of bone marrow involvement on outcome in relapsed and refractory transplant eligible diffuse large B-cell lymphoma and transformed indolent lymphoma’, PLoS ONE, 15(7 July). Available at: https://doi.org/10.1371/journal.pone.0235786.

Mohme, M. et al. (2020) ‘Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma’, Clinical Cancer Research, 26(11), pp. 2626–2639. Available at: https://doi.org/10.1158/1078-0432.ccr-19-0803.

Schorb E et al. (2020) ‘Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.’, British journal of haematology, 189(5), pp. 879–887. Available at: https://doi.org/10.1111/bjh.16451.

Tintelnot, J. et al. (2020) ‘Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - The randomized phase 2 INTEGA trial (AIO STO 0217)’, BMC Cancer, 20(1). Available at: https://doi.org/10.1186/s12885-020-06958-3.

Gryaznov, D. et al. (2020) ‘Rationale and design of repeated cross-sectional studies to evaluate the reporting quality of trial protocols: the Adherence to SPIrit REcommendations (ASPIRE) study and associated projects’, Trials, 21(1), p. 896. Available at: https://doi.org/10.1186/s13063-020-04808-y.